Early-Phase Drug Development Is Getting Harder. Traditional CROs Weren’t Built for It.

Biology is harder to predict. Regulators expect more. Sponsors need decision-ready human data earlier than ever. Inside this guide, we show how an integrated early-phase partner helps you move from preclinical planning into Phase I and II with confidence. 
Get the Guide

Choosing an early-phase partner looks straightforward. It rarely is.

Promising programmes rarely stall because the science was wrong. They stall at the handoffs between consultants, labs, clinical sites and trial teams who aren’t working from the same plan. Getting early-phase right takes more than a vendor list. It takes connected scientific expertise, specialist sites and a team that has made these decisions before. Today’s sponsors are working through:

  • Pressure to generate robust human data earlier, before committing to larger trials
  • Go/no-go decisions that need early efficacy signals, not just safety data
  • Regulatory expectations that shape the programme long before IND or CTA submission
  • Handoffs between separate providers that cost time, data continuity and momentum
  • Specialist populations, from renal and hepatic impairment to women’s health, that are hard to recruit predictably
hvivo_brochure_image

hVIVO Delivers Across Early-Phase Development

This guide outlines how hVIVO’s consulting, laboratory, clinical and Human Challenge capabilities work together, so you can get on with progressing your programme.

One brochure. Every early-phase capability you need to evaluate.

Scientific Leadership

Experienced scientific, medical and operational leaders guiding your programme from study design through delivery. 

Integrated Early-Phase Ecosystem

 Consulting, laboratories, clinical trials and Human Challenge Trials under one roof. Use one service or combine them. 

Human Challenge Trial Expertise

 World-leading experience in controlled human infection studies, generating early efficacy signals sooner than field studies. 

Advanced Laboratory Capabilities

Bioanalytical, virology, immunology and biomarker expertise supporting work from R&D through to large Phase III studies.

Specialist Clinical Sites

Purpose-built units in London, Mannheim, Kiel and Berlin, with characterised patient populations and rapid recruitment pathways. 

Drug Development Consulting

Non-clinical, clinical, CMC, PK and regulatory consulting, from IND-enabling strategy through to regulator interactions.

Therapeutic Area Depth

Infectious disease, respiratory, cardiometabolic, dermatology, women’s health, and renal and hepatic impairment.

Built by the scientific and medical leaders behind hVIVO.

The expertise in this guide comes from hVIVO’s multidisciplinary team, spanning clinical pharmacology, respiratory medicine, infectious disease, cardiometabolic research, statistics, regulatory strategy, bioanalysis and drug development consulting. Our leaders work across our sites in London, Mannheim, Kiel and Berlin to help sponsors tackle complex development challenges and generate decision-ready data.

andrew-catchpole-leadership-300x300-1
Andrew Catchpole

Chief Scientific Officer

Thomas Forst
Prof Thomas Forst

Chief Medical Officer

hvivo-Chris-Forsdyke
Chris Forsdyke

Head of Laboratories

hvivo-alex-mann
Alex Mann

Director, Clinical Science

Martin-Larke
Martin Larke

Principal Biostatistician

hvivo-Katsuhiro-Mihara
Katsu Mihara

Head of Clinical Development & PK/PD

hvivo-erik-gout
Erik Gout

Head of CMC

Our Accreditations

Good Clinical Practice (GCP)

Good Clinical Practice (GCP) is an international ethical and scientific quality standard; for designing, conducting, recording and reporting trials. Ensuring participant safety prevails over the interests of science and society.

 

HVIVO-ACCREDITATION-MHRA

 

Human Tissue Authority (HTA)

hVIVO is accredited by the Human Tissue Authority (HTA), meaning that we have been recognized by the HTA as compliant with standards and regulations for the ethical and legal removal, storage, and use of human tissue. A HTA license is essential, as hVIVO handles human tissue for various research purposes.

 

HVIVO-ACCREDITATION-HTA

 

Good Clinical Laboratory Practice (GCLP)

All clinical trials comply with GCP and/or GCP for Laboratories (GCLP) guidance. Human Challenge Agent-only clinical studies that do not involve IMP also comply with GCP/GCLP. 

 

HVIVO-ACCREDITATION-MHRA

 

hVIVO is a UKAS accredited Testing Laboratory No. 27882